Introduction to the application and indications of everolimus (Afinitor) in the treatment of breast cancer

Everolimus is an oral mTOR (mammalian target of rapamycin) inhibitor that mainly inhibits cancer cell proliferation, angiogenesis and tumor growth by blocking the mTOR signaling pathway. In the treatment of breast cancer, everolimus is often used in the combined treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, especially when patients are resistant to aromatase inhibitors. Its mechanism of action can delay the occurrence of drug resistance, improve the efficacy of endocrine therapy, and provide new treatment options for patients.

Clinical studies have shown that the combined use of everolimus and exemestane can significantly extend progression-free survival (PFS) and improve disease control rate. For breast cancer patients who have received endocrine therapy and whose disease has progressed, this combination regimen can delay further progression of the disease and improve the quality of life of some patients. In addition, everolimus is convenient to take orally, has high treatment compliance, and is also convenient for long-term maintenance treatment.

The indications of everolimus in breast cancer are mainly for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, especially when endocrine therapy is ineffective or drug-resistant. Its scope of application emphasizes combined endocrine therapy, rather than the use of single drug therapy alone, and specific plans need to be formulated based on the individualized evaluation of doctors. Caution or dose adjustment should be used in patients with renal insufficiency or severe infection.
In terms of safety, everolimus may cause side effects such as stomatitis, rash, fatigue, pneumonia, and increased blood sugar. During use, blood routine, liver and kidney function, and blood sugar levels need to be monitored regularly to detect and deal with adverse reactions in a timely manner. Overall, everolimus provides an effective targeted combination treatment option for breast cancer patients, but it should be used under the guidance of a professional doctor and an individualized treatment plan should be designed based on the patient's specific condition.
Reference: https://www.drugs.com/